List of Figures
Figure 1: PI3K Marketed and Pipeline Landscape, Global, PI3K Signaling Network, 2018 8
Figure 2: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the PI3K/AKT/mTOR Pathway, 2018 16
Figure 3: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the PI3K/AKT/mTOR Pathway by Molecule Type, 2018 17
Figure 4: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the PI3K/AKT/mTOR Pathway by Therapy Area, 2018 18
Figure 5: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the Ras/Raf/MER/ERK Pathway, 2018 19
Figure 6: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the Ras/Raf/MER/ERK Pathway by Molecule Type, 2018 19
Figure 7: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the Ras/Raf/MER/ERK Pathway by Therapy Area, 2018 20
Figure 8: PI3K Marketed and Pipeline Landscape, Gloal, Marketed Activity for Cell Survival Pathways Downstream of AKT, 2018 21
Figure 9: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Survival Pathways Downstream of AKT by Molecule Type, 2018 21
Figure 10: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Survival Pathways Downstream of AKT by Therapy Area, 2018 22
Figure 11: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Cycle Progression Pathways Downstream of AKT, 2018 23
Figure 12: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Cycle Progression Pathways Downstream of AKT by Molecule Type, 2018 24
Figure 13: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Cycle Progression Pathways Downstream of AKT by Therapy Area, 2018 24
Figure 14: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Kinases Downstream of PDK1, 2018 25
Figure 15: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Kinases Downstream of PDK1 by Molecule Type, 2018 25
Figure 16: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Kinases Downstream of PDK1 by Therapy Area, 2018 26
Figure 17: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Herceptin ($bn), 2006–2024 27
Figure 18: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Avastin ($bn), 2006–2024 28
Figure 19: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Lantus (insulin glargine) ($bn), 2006–2024 29
Figure 20: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Eylea (aflibercept) ($bn), 2011–2024 30
Figure 21: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Ibrance (palbociclib) ($bn), 2015–2024 31
Figure 22: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Novolog ($bn), 2006–2024 32
Figure 23: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Humalog ($bn), 2006–2024 33
Figure 24: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Perjeta ($bn), 2012–2024 34
Figure 25: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Avonex ($bn), 2006–2024 35
Figure 26: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Levemir (insulin detemir) ($bn), 2006–2023 36
Figure 27: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway, 2018 45
Figure 28: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Novelty, 2018 47
Figure 29: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Stage of Development, 2018 48
Figure 30: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Molecule Type, 2018 49
Figure 31: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Therapy Area, 2018 50
Figure 32: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway, 2018 50
Figure 33: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Novelty, 2018 51
Figure 34: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Stage of Development, 2018 51
Figure 35: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Molecule Type, 2018 52
Figure 36: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Therapy Area, 2018 53
Figure 37: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT, 2018 54
Figure 38: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Novelty, 2018 55
Figure 39: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Stage of Development, 2018 56
Figure 40: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Molecule Type, 2018 57
Figure 41: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Therapy Area, 2018 58
Figure 42: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT, 2018 59
Figure 43: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Novelty, 2018 59
Figure 44: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Stage of Development, 2018 60
Figure 45: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Molecule Type, 2018 61
Figure 46: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Therapy Area, 2018 62
Figure 47: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT, 2018 63
Figure 48: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity Metabolism Pathways Downstream of AKT by Novelty, 2018 63
Figure 49: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT by Stage of Development, 2018 64
Figure 50: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT by Molecule Type, 2018 65
Figure 51: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT by Therapy Area, 2018 66
Figure 52: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1, 2018 66
Figure 53: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Novelty, 2018 67
Figure 54: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Stage of Development, 2018 67
Figure 55: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Molecule Type, 2018 68
Figure 56: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Therapy Area, 2018 69